Descripción de la empresa
Alector, Inc. operates as a clinical-stage biotechnology entity dedicated to developing therapeutic interventions aimed at countering the progression of neurodegeneration within the United States market. The company functions within the broader healthcare sector, specifically focusing on the biotechnology industry, which involves the application of biological processes to develop products for treating prevalent neurodegenerative diseases. As of the latest reporting period, the organization employs 103 individuals and holds a total market capitalization of $272.60M while generating annual revenue of $21.05M. These financial figures indicate that the company maintains a relatively small market capitalization compared to established pharmaceutical peers, reflecting its status as a capital-intensive venture in the early to mid-stages of product development where revenue generation is currently limited to a single fiscal year.
Salud financiera
The company reported a revenue of $21.05M over the trailing twelve months, yet recorded a net income of -$142,928,992 and an EBITDA of -$147,367,008, highlighting a significant disparity between top-line sales and bottom-line profitability. This substantial gap between revenue and net income reveals a cost structure heavily burdened by research and development expenditures and operational expenses that far exceed current sales, which is typical for clinical-stage biotechnology firms. Free cash flow stands at -$114,339,128, indicating that the company is currently consuming cash reserves rather than generating liquidity from its operations, which constrains immediate financial flexibility for expansion without external funding. All three margin metrics reflect this financial reality: the gross margin is 0.0%, the operating margin is -587.5%, and the profit margin is 0.0%, collectively indicating that the company is not yet profitable at any level of operational efficiency. In terms of leverage, the company holds $256.02M in cash against $36.23M in debt, resulting in a debt-to-equity ratio of 118.22, which suggests a balance sheet that is highly leveraged relative to equity despite the presence of significant cash on hand. The current ratio of 3.83 demonstrates a strong position regarding short-term liquidity, suggesting the company possesses sufficient current assets to cover its short-term liabilities multiple times over. Furthermore, the return on equity is -181.6% and the return on assets is -25.1%, metrics that reveal that management effectiveness in generating profit from shareholder investments and total assets is currently negative due to the pre-commercial nature of the business.
Evaluación de valoración
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is -2.80, a valuation metric that implies the market expects earnings to remain negative or for the company to require significant capital before becoming profitable. The price-to-book ratio stands at 8.88, indicating that the market values the company at a significant premium over its net asset value, likely driven by the intangible value of the intellectual property and the pipeline assets rather than current book equity. Alternative valuation metrics such as the price-to-sales ratio of 12.95 and the EV/EBITDA of -0.36 suggest that investors are pricing the stock based on future revenue potential and pipeline milestones rather than current cash flows or earnings power. The stock has traded between a 52-week low of $0.87 and a 52-week high of $3.40, meaning the current price sits within a volatile range that reflects high uncertainty regarding the timing of clinical trial results and regulatory approvals. With a beta of 0.58, the stock exhibits lower volatility relative to the broader market, suggesting that its price movements are less sensitive to general market fluctuations compared to the average large-cap equity.
Growth & Income
Revenue growth year-over-year has declined by 88.5%, while earnings growth is N/A due to the absence of reported earnings, indicating that the company is currently in a phase of scaling operations or managing revenue recognition rather than expanding sales volume. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the organization reinvests all available capital and retains all earnings to fund ongoing research, development, and clinical trials rather than distributing income to shareholders. This reinvestment strategy is characteristic of clinical-stage biotechnology companies that prioritize long-term pipeline advancement over immediate income distribution to investors. Overall, the growth and income profile for Alector, Inc. is defined by negative revenue growth and a complete absence of dividend income, reflecting the capital-intensive lifecycle of developing therapies for neurodegenerative diseases before they reach commercial launch.